TLR4-IN-C34 attenuates the progression of osteoarthritis through inhibiting inflammation, angiogenesis and pain
Cellular Signalling · 2025
DOI: 10.1016/j.cellsig.2025.112084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2025. Verfasst von Kang Wei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, PR China.; Department of Plastic Surgery, Zhon…. Hauptthemen laut MEDLINE: Toll-Like Receptor 4, Osteoarthritis, Inflammation, Neovascularization, Pathologic. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Science and Technology of Hubei Province, National Natural Science Foundation of China, Department of Science and Technology, Hubei Provincial People's Government.
Abstract (Originalsprache)
Osteoarthritis (OA), a common degenerative articular disease, is symbolized as joint pain and functional impairment. Chronic inflammation, oxidative stress, and chondrocyte apoptosis are characteristics of the OA pathogenesis. Single-cell RNA sequencing (scRNA-seq) and immunofluorescence of human cartilage demonstrated that the Toll-like receptors 4 (TLR4) expression was increased in OA patients and the function of TLR4 was activated. As specific TLR4 inhibitor, we demonstrated in vitro and in vivo that C34 inhibited the catabolism of chondrocytes and promoted anabolism. C34 restrained pain response, alleviated the lameness, and suppressed expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in mice after destabilized medial meniscus (DMM) surgery. Additionally, C34 restrained angiogenesis associated with OA. Mechanistically, C34 was attributed to suppressing the NF-κB signaling pathways. Our results showed that C34 had anti-OA effects both in vitro and in vivo. These results suggest that targeting TLR4 offered promising therapeutic potential for OA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, PR China.; Department of Plastic Surgery, Zhongnan Hospital of Wuhan University, 169 East Lake Road, Wuchang Distric…
- Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan 430030, PR China.
- Department of Obstetrics and Gynecology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, 100 Xianggang Road, Wuhan 430000, PR China.
- Department of Orthopedic Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, PR China.. Electronic address: hui_liu@whu.edu.cn.
- Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan 430030, PR China.. Electronic address: liuchangyutj@hust.edu.cn.
Förderung
- Department of Science and Technology of Hubei Province
- National Natural Science Foundation of China
- Department of Science and Technology, Hubei Provincial People's Government
Zitieren
APA
Wei, K., Zou, Y., Xu, H., Liu, H., & Liu, C. (2025). TLR4-IN-C34 attenuates the progression of osteoarthritis through inhibiting inflammation, angiogenesis and pain. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2025.112084
Vancouver
Wei K, Zou Y, Xu H, Liu H, Liu C. TLR4-IN-C34 attenuates the progression of osteoarthritis through inhibiting inflammation, angiogenesis and pain. Cellular Signalling. 2025. doi:10.1016/j.cellsig.2025.112084
BibTeX
@article{Wei2025,
author = {Wei, Kang and Zou, Yi and Xu, Huanhuan and Liu, Hui and Liu, Changyu},
title = {TLR4-IN-C34 attenuates the progression of osteoarthritis through inhibiting inflammation, angiogenesis and pain},
journal = {Cellular Signalling},
year = {2025},
doi = {10.1016/j.cellsig.2025.112084}
}
EUVIMED